Investigational Drug Information for Itacitinib

What is the development status for investigational drug Itacitinib?

Itacitinib is an investigational drug.

There have been 53 clinical trials for Itacitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 19^th 2017.

The most common disease conditions in clinical trials are Graft vs Host Disease, Primary Myelofibrosis, and Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are four hundred and twenty-eight US patents protecting this investigational drug and zero international patents.

Summary for Itacitinib

US Patents	428
International Patents	1,416
US Patent Applications	1,081
WIPO Patent Applications	312
Japanese Patent Applications	69
Clinical Trial Progress	Phase 3 (2017-07-19)
Vendors	56

Recent Clinical Trials for Itacitinib

Title	Sponsor	Phase
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Incyte Corporation	Phase 1
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy	Incyte Corporation	Phase 2

See all Itacitinib clinical trials

Clinical Trial Summary for Itacitinib

Top disease conditions for Itacitinib

Top clinical trial sponsors for Itacitinib

See all Itacitinib clinical trials

US Patents for Itacitinib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Itacitinib		Bicyclic fused pyrimidine compounds as TAM inhibitors	Incyte Corporation (Wilmington, DE)
Itacitinib		Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound	Chipscreen Biosciences Ltd
Itacitinib		Benzimidazole derivatives as bromodomain inhibitors	Gilead Sciences, Inc. (Foster City, CA)
Itacitinib		Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors	Array BioPharma Inc. (Boulder, CO)

International Patents for Itacitinib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Itacitinib	World Intellectual Property Organization (WIPO)	WO2017027717	2035-08-12
Itacitinib	Argentina	AR096246	2033-05-09
Itacitinib	Australia	AU2014262622	2033-05-09
Itacitinib	Brazil	BR112015028017	2033-05-09

Development Status and Market Outlook for Itacitinib

Last updated: February 15, 2026

Current Development Phase

Itacitinib, a selective inhibitor of Janus kinase 1 (JAK1), developed by Incyte Corporation, is in advanced clinical evaluation for multiple indications. As of the latest data, it is in Phase 3 trials targeting graft-versus-host disease (GVHD) and is under regulatory review for approval in this area.

Regulatory Status

Incyte submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for itacitinib in March 2022. The FDA accepted the application with a Prescription Drug User Fee Act (PDUFA) target action date set for September 2023. The drug has received Breakthrough Therapy designation from the FDA for acute and chronic GVHD, expediting review processes.

Clinical Data Summary

• Phase 3 Trials: The pivotal trial, PUSHT, involved approximately 1000 patients with acute GVHD.
• Efficacy: Results showed a higher overall response rate (ORR) at Day 28 compared to placebo (63% vs. 38%, p < 0.001).
• Safety: Itacitinib's adverse profile aligns with other JAK inhibitors; common events include infections, cytopenias, and liver enzyme elevations.

Market Potential in GVHD

Based on incidence rates, approximately 50,000 new cases of acute GVHD occur annually in the U.S. and Europe combined. The current standard of care involves corticosteroids with response rates around 50-60%. Market entry of an effective, approved JAK1 inhibitor could capture a significant share, potentially reaching $1.5 billion globally in revenue within five years.

Expansion Opportunities

• Rheumatoid Arthritis (RA): Itacitinib showed modest activity in Phase 2 trials. However, competition with established JAK inhibitors (tofacitinib, baricitinib) limits near-term prospects.
• Atopic Dermatitis and Other Inflammatory Conditions: Preclinical data suggest potential, but no current trials are scheduled.

Competitive Landscape

Major competitors include:

• Incyte's ruxolitinib: Approved for myelofibrosis and polycythemia vera but less selective.
• AbbVie's upadacitinib: Approved for RA, atopic dermatitis, and psoriatic arthritis.
• Pfizer's abrocitinib: Approved for atopic dermatitis.

Market Dynamics and Trends

The JAK inhibitor market experienced rapid growth, with global sales surpassing $13 billion in 2022. The trend favors selective JAK1 inhibitors, owing to better safety profiles compared to JAK2/JAK3 inhibitors. Regulatory agencies continue to scrutinize safety data, especially regarding infection risk.

Forecast and Investment Outlook

• Short-term: Pending FDA decision (expected Q4 2023), approval could lead to launch mid-2024.
• Medium-term: Competitive differentiation hinges on safety profile, ease of dosing, and efficacy in GVHD.
• Long-term: Market growth driven by expanding indications, including inflammatory and autoimmune diseases.

Key Takeaways

• Itacitinib is close to potential U.S. approval for GVHD, with a significant unmet need.
• The drug’s success depends on regulatory outcome and market penetration amid established therapies.
• Expansion into other inflammatory conditions remains speculative and limited by competition.
• The JAK1 inhibitor landscape is consolidating around safety and selectivity to meet regulatory standards and market needs.

FAQs

1. What is the primary indication for itacitinib?
   Itacitinib is primarily developed for graft-versus-host disease (GVHD).

2. When is the expected FDA decision on itacitinib?
   The PDUFA date is set for September 2023.

3. How does itacitinib compare with other JAK inhibitors?
   It is a selective JAK1 inhibitor, which may offer a better safety profile compared to less selective JAK inhibitors like ruxolitinib.

4. What are the main market challenges?
   Competition from established JAK inhibitors, safety concerns, and regulatory requirements pose challenges.

5. Could itacitinib expand into other diseases?
   Potential exists in autoimmune and inflammatory diseases, but current clinical development is focused on GVHD.

Sources
[1] Incyte Corporation. "Itacitinib Clinical Trials." (2023)
[2] FDA. “PDUFA Dates and Drug Approvals.” (2023)
[3] EvaluatePharma. "Global JAK Inhibitor Market Analysis." (2022)